Imatinib is a TKI targeting C-KIT, PDGFR, and ABL and has already demonstrated satisfactory activity in patients with chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST) (90–92). The gene discussed is KIT; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.